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Ethnic Disparities in Cervical Cancer Survival Among
Medicare Eligible Women in a Multiethnic Population
Ann L. Coker, PhD,* Katherine S. Eggleston, MSPH,Þ
Xianglin L. Du, MD, PhD,Þ and Lois Ramondetta, MDþ
Objectives: To determine predictors of cervical cancer survival by socioeconomic status (SES), urbanization,
race/ethnicity, comorbid conditions, and treatment among elderly Medicare-eligible women whose conditions were
diagnosed with cervical cancer in a multiethnic population.
Methods: A total of 538 women with cervical cancer aged 65 years or older were identified from 1999 to 2001
from the Texas Cancer Registry and were linked with the state Medicare data and Texas Vital Records to determine
survival times. All women had similar access to care through Medicare fee-for-services insurance. A composite
measure of SES was created using census tract-level data as was urbanization. Treatment and comorbid conditions
were available from the Medicare data. Cox proportional hazards modeling was used for all-cause and cervical
cancerYspecific survival analysis.
Results: Increased age (P G 0.0001) and advanced tumor stage (P G 0.0001) were associated with poorer all-
cause and cervical cancerYspecific survival. Having a comorbid condition was associated with all-cause survival
(P G 0.01) but not cervical cancerYspecific mortality. After adjusting for confounders, women receiving some form
of treatment were almost half as likely to die with cervical cancer (adjusted hazard ratio = 0.68; 95% confidence
interval, 0.52Y0.89). After adjustment for all confounders, Hispanic women consistently had lower all-cause and
cervical cancerYspecific mortality rates relative to non-Hispanic white and non-Hispanic black women.
Conclusions: Among women with similar health care coverage, Hispanic women had consistently lower all-cause
and cervical cancerYspecific mortality rates than other older women whose conditions were diagnosed with this
disease in Texas. The presence of comorbid conditions and treatment were important predictors of survival, yet
these factors do not explain the survival advantage for Hispanic women.
Key Words: Race, Ethnicity, Cervical neoplasia, Survival, Medicare, Elderly, Socioeconomic status, Comorbid
conditions, Treatment
(Int J Gynecol Cancer 2009;19: 13Y20)
Poorer survival rates among minority populations whose condi-tions were diagnosed with cervical cancer have been well docu-
mented,1 although the reason for this disparity of poorer outcomes
remains unclear. Differences in stage at diagnosis, number of co-
morbid conditions, timeliness of treatment received, age, urbaniza-
tion, and socioeconomic status (SES) may explain this survival
disparity. Newmann and Garner2 conclude in their meta-analysis
that social inequality, defined by race and SES, is associated with
an increased risk of cervical cancer incidence, yet social inequi-
ties have not been consistently established as independent risk fac-
tors for poorer cervical cancer survival. Of the 17 studies with at
least 100 cervical cancer cases,3Y19 7 found that race/ethnicity
remained associated with poorer survival after adjusting for age,4
stage,8 SES,7,19 and treatment.3,6,9 The evolving literature address-
ing proxy measures of SES and survival is more consistent.
Six10,12,13,19Y21 of the 11 studies7,10,12,13,18Y21 find that lower SES
is associated with poorer survival when adjusting for age, stage,
tumor characteristics, and race. Two large studies conducted among
those with similar access to health care found that SES18 and race14
were not associated with survival. Although age is an important
factor for survival after a cervical cancer diagnosis, existing studies
are mixed in finding that increasing age is associated with poorer
survival after controlling for confounders.3Y5,8Y10,13,22Y36 Few stud-
ies have addressed the patterns of care and survival among elderly
women.18,24
The purpose of this study was to estimate cervical cancer
survival by demographic factors, comorbidities, and treatment
among women aged 65 years and older whose conditions were
diagnosed with cervical cancer and were reported to the Texas
Cancer Registry (TCR). All women included in this analysis were
Medicare-eligible based on age alone (aged Q65 years).
METHODS
Study Population and Data Sources
We conducted a population-based survival analysis among
women aged 65 years and older whose conditions were diagnosed
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with cervical cancer and were reported to the TCR from 1999 to
2001. Institutional review boards from the Texas Department of
State Health Services and the University of Texas Health Science
Center at Houston approved the study protocol. These dates were
selected because these were the most recent Medicare and TCR
data available at the time the study was funded. Data from Texas
Vital Records were used to determine survival dates and cause of
death. Only invasive cervical cancer cases were included in this
analysis; carcinoma in situ cases were excluded by the TCR. All
cancer cases were geocoded to the block group level based on the
address given at the time of diagnosis. This cohort of cervical can-
cer cases was then merged using social security numbers with
Texas Medicare files from 1999 to 2001. Medicare claims files
included the denominator record of all enrolled participants, Medi-
care provider analysis file, outpatient, and inpatient claims records.
Medicare data provided information on whether treatment was re-
ceived, on the type and timing of treatment, and on the number of
comorbid conditions.
Demographic Attributes
Data from the TCR, originally abstracted from medical
records, were used to define age at diagnosis, race/ethnicity, stage
at diagnosis, and cancer cell type. Race/ethnicity was classified
using both race and Spanish/Hispanic origin and comprised the
following categories: non-Hispanic white, non-Hispanic black, and
Hispanic. The TCR uses SEER summary staging, which was then
categorized for analysis as follows: early (stage 1), late (stages 2Y7),
and unknown stage (stage 9). Cervical cancer cell types were
grouped as squamous and nonsquamous owing to established dif-
ferences in cancer prognosis. No smoking data are available from
both Medicare and TCR.
Neighborhood SES and Urbanization
The following block groupYlevel data from the United States
2000 were used as indicators of neighborhood SES: median house-
hold income, proportion below poverty, proportion with a college
education, proportion with a management/professional occupation,
and median home value. Principal factor analysis was performed
to retain one factor representing a composite SES, which was
then categorized into tertiles based on the distribution in the Texas
population. This methodology has been supported and used in pre-
vious health research.37Y39 The Rural Urban Commuting Area
Codes, which use population density, urbanization, and daily
commuting, available at the census track level, were used to define
aggregate levels of urbanization.40 Categorization A, which approx-
imates the metro/nonmetro split at the census track level, was used
to describe the data.41 The following categories were used: urban
focused, large town, small/isolated town.
Comorbid Conditions
On the basis of an accepted measure of comorbidity,42 co-
morbid conditions were identified from Medicare claims files and
corresponded to diagnoses made or procedures consequent to co-
morbidities in the year before the cervical cancer diagnosis. Two
comorbidity indexes were used: the Charlson Index43 and the count
of number of unique diagnosis codes,44 with modifications sug-
gested by Fleming et al45 to provide a comprehensive index for
women. The Charlson Index is a weighted count of a range of con-
ditions diagnosed within 1 year of the cervical cancer. These condi-
tions include heart disease, other cancers, hypertension, diabetes,
stroke, other vascular disease, chronic obstructive pulmonary dis-
ease, dementias, moderate to severe liver disease, chronic renal
failure, and ulcers. The higher the index score, the more severe the
burden of comorbidity. Anemia (International Classification of Dis-
eases, Ninth Revision [ICD-9], 280-285) diagnosed within 30 days
of cervical cancer was also included as a specific condition, which,
although not necessarily comorbid to cervical cancer, may influence
survival.
Treatment
Data corresponding to treatment received were abstracted
from Medicare outpatient, inpatient, and physician claim files.
Potential treatments included conization of the cervix, surgery
(hysterectomy), chemotherapy, and/or radiation as indicated in the
guidelines by the National Cancer Institute for cancers staged I to
IV5. The following codes were used to define cone, chemotherapy,
surgery, and radiation. Cone: ICD-9 procedure codes (67.2, 67.3,
67.32, 67.33) and Common procedure codes (57520, 57522, 57510,
57511, 57513). Chemotherapy: ICD-9 procedure codes (9925), ICD-9
diagnostic codes (V58.1, V66.2, V67.2), Common procedure codes
(96400-96549, J9000-J9999, Q0083-Q0085), and Revenue center
codes (0331, 0332, 0335). Radiation therapy: ICD-9 procedure codes
(9221-9229), ICD-9 diagnostic codes (V58.0, V67.1), Common
procedure codes (77401-77499, 77750-77799), and Revenue center
codes (0330, 0333). Surgery: ICD-9 procedure codes (68.3-68.9) and
Common procedure codes (51925, 56308, 58150, 58152, 58200,
58180, 58210, 58240, 58260-58270, 58275, 58280, 58285).
Treatment included any claim containing the equivalent diag-
nostic, procedure, and/or revenue center codes dated 6 months be-
fore diagnosis (to allow for lag time in cancer reporting) and up to
1 year after diagnosis. Information on the type of hospital or faci-
lity where treatment was received was not available. Dichotomous
variables were created indicating (1) any treatment compared with
no treatment; (2) surgery (primarily hysterectomy or cone biopsy);
(3) radiation or chemotherapy alone; (4) radiation and chemothe-
rapy alone; (5) radiation, chemotherapy, and surgery; and (6) sur-
gery and radiation or chemotherapy. Because we are using claims
data, we have no information on treatment delays or the com-
pleteness of treatment series. Logistic regression analysis in
STATA was performed to assess multivariate predictors of receiv-
ing any treatment, as well as individual treatment options.
Cancer Survival
Information on date and cause of death was available from
Texas Vital Statistics Bureau for all diagnosed cancer cases through
December 2003. Survival days were calculated based on the diag-
nosis date (available from TCR data) and the corresponding date
of death; those who were still surviving at the end of the follow-
up period were censored in subsequent survival analysis (all-cause
and cervical cancerYspecific). Survival follow-up times were ac-
crued through December 2003 and ranged from 0 to 1825 days.
Statistical Analysis
From 1999 to 2001, 688 cases of cervical cancer among
women aged 65 years and older were reported to the TCR. Of
these cases, 604 had a corresponding record of enrollment in
Medicare during the same period. One case was excluded because
of inadequate geocoding information to determine SES and urba-
nization. The average time to treatment in this sample was 27.20
days; thus, to allow adequate time for treatment, an additional
47 cases were excluded diagnosed between October 1, 2001, and
December 31, 2001 (n = 556). Cases with unknown race/ethnicity
were also excluded from analysis (n = 18). The final sample size
for analysis was 538. Logistic regression was used to determine
correlates of receiving any type of treatment within 12 months.
Cox proportional hazards modeling was used to estimate the
relative rate of dying from any cause as well as cervical cancer
among those whose conditions were diagnosed with this disease
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from 1999 to 2001. Deaths identified through the death certificate
alone (n = 47) were excluded, resulting in a survival analysis of
491 women. To better evaluate the effect of race/ethnicity, so-
ciodemographic factors, comorbid conditions, and treatment on
survival, we included all factors in one model with time to death as
the outcome. The treatment variables included 6 dichotomous var-
iables indicating the type and combination of treatment received.
The number of chemotherapy and/or cycles of radiation received
was also included in the model. We also created a dichotomous
variable indicating whether the woman received any treatment
(yes vs no). The multivariate model used was a semiparametric
regression modeling procedure describing the risk relationship be-
tween survival time and predictor variables and assumed that the
underlying hazard rate is a function of the covariates. No assump-
tions were made about the nature or shape of the hazard function.
All data were analyzed using STATAVersion 9.
RESULTS
Table 1 presents the demographic attributes by race/ethnicity,
stage at diagnosis, cervical cancer cell type, number of comorbid
conditions, and treatment received by type. The mean (SD) age at
diagnosis for this cohort of women aged 65 years and older diag-
nosed with cervical cancer was 76.0 (7.9) years and ranged
from 65 to 103 years. Although 92% of this cohort had a Medicare
claim in the period under study, 31% had claim indicating treatment.
Non-Hispanic black and Hispanic cervical cancer cases were signi-
ficantly more likely to reside in lower SES neighborhoods relative
to non-Hispanic white cases.
TABLE 1. Demographic characteristics of women aged 65 years and older whose conditions were diagnosed with cervical
cancer and reported to the TCR from 1999 to 2001 using Medicare-linked treatment data
Individual-level
characteristics
All women
(n = 538), n (%)
Non-hispanic white
(n = 304), n (%)
Non-hispanic black
(n = 99), n (%)
Hispanic
(n = 135), n (%)
Neighborhood SES*
SES high 136 (25.3) 103 (33.9) 16 (16.2) 17 (12.6)
SES intermediate 166 (30.9) 114 (37.5) 24 (24.2) 28 (20.7)
SES low 236 (43.8) 87 (28.6) 59 (59.6) 90 (66.7)
Urbanization
Urban 418 (77.7) 230 (75.6) 79 (79.8) 109 (80.7)
Large town 62 (11.5) 34 (11.2) 9 (9.1) 19 (14.1)
Small town/rural 58 (10.8) 40 (13.2) 11 (11.1) 7 (5.2)
Cell type
Squamous carcinomas 424 (78.8) 232 (76.3) 79 (79.8) 113 (83.7)
Nonsquamous 114 (21.2) 72 (23.7 20 (20.2) 22 (16.3)
Stage at diagnosis
Localized 179 (33.3) 109 (35.9) 28 (28.3) 42 (31.1)
Regional/distant 219 (40.7) 114 (37.5) 47 (47.5) 58 (43.0)
Unstaged/unknown 140 (26.0) 81 (26.64) 24 (24.2) 35 (25.9)
Comorbid conditions
None 339 (63.0) 195 (64.1) 61 (61.6) 83 (61.5)
One 112 (20.8) 68 (22.4) 17 (17.2) 27 (20.0)
Two or more 87 (16.2) 41 (13.5) 21 (21.2) 25 (18.5)
Medicare claim (1999Y2001)
No claim 44 (8.2) 32 (10.5) 6 (6.1) 6 (4.4)
Claim 494 (91.8) 272 (89.5) 93 (93.9) 129 (95.6)
Treatment†
No treatment received 166 (30.86) 99 (32.6) 33 (33.3) 34 (25.2)
Treatment received 372 (69.14) 205 (67.4) 66 (66.7) 101 (74.8)
All treatments received
No treatment 166 (30.86) 99 (32.57) 33 (33.33) 34 (25.19)
Surgery/cone alone 50 (9.29) 33 (10.86) 7 (7.07) 10 (7.41)
Radiation/chemotherapy alone 81 (15.06) 43 (14.14) 15 (15.15) 23 (15.56)
Radiation and chemotherapy 85 (15.80) 41 (13.49) 11 (11.11) 33 (23.7)
Radiation, chemotherapy, and surgery 64 (11.90) 39 (12.83) 10 (10.10) 15 (12.59)
Radiation/chemotherapy and surgery 92 (17.10) 49 (16.12) 23 (23.23) 20 (15.55)
*Socioeconomic status (SES) is a composite variable categorized into tertiles based on the distribution of Texas residents.
†Treatment includes 6 months before diagnosis and 1 year after diagnosis.
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Among Medicare-eligible cervical cancer cases, those with
an unknown stage at diagnosis were less likely to receive any type
of treatment, whereas those with a comorbid condition and younger
women were more likely to receive treatment (Table 2). We repeated
the logistic analysis using multilevel modeling and found very
similar effect estimates to those presented in Table 3, yet as antici-
pated, the confidence intervals (CIs) were less precise.
Table 3 presents our multivariable analyses from Cox
proportional hazards modeling for all-cause survival and cervical
cancerYspecific survival separately. Models included individual at-
tributes of the cancer case (eg, age, stage, cell type, race/ethnicity),
neighborhood attributes of SES and urbanization, comorbid condi-
tions, and treatment received.
Demographic Factors
Older women and those whose conditions were diagnosed
at a late or unknown stage were significantly more likely to die and
to die of cervical cancer. Although rural residence was not associ-
ated with an all-cause mortality, those living in large towns had
almost a 90% increase in risk of dying of cervical cancer. Hispa-
nic women with cervical cancer were less likely die relative to non-
Hispanic white or black women. The all-cause mortality rate was
highest for non-Hispanic blacks (9.28 per 1000 woman-days) fol-
lowed by non-Hispanic whites (7.50) and was lowest for Hispanic
women (4.57). The same pattern was also true for cervical cancerY
specific mortality.
Comorbidity
Women who had one or more comorbid conditions were
40% more likely to die when compared with those who did not
have a comorbid condition after adjusting for all other factors.
Similarly, having anemia at diagnosis was associated with a 59%
increase in all-cause mortality and was elevated but not signifi-
cant for cervical cancerYspecific mortality when compared with
women having no anemia noted in Medicare files.
Treatment
Receiving any form of treatment was associated with a re-
duced risk of dying but not with cervical cancerYspecific mortality.
Receiving surgery (cone biopsy or hysterectomy) alone or in com-
bination with radiation or chemotherapy was associated with lower
mortality rates relative to women not receiving treatment and ad-
justing for stage, cell type, and the remaining demographic factors.
Although not presented in Table 3, increasing weeks to first treat-
ment, independent of the type of treatment, was associated with
slightly higher mortality (adjusted hazard ratio [aHR], 1.001Y1.012;
P = 0.02) yet not cervical cancerYspecific mortality (P = 0.48). The
number of radiation or chemotherapy claims was not associated
with all-cause or cervical cancerYspecific survival.
Because stage determines treatment options, we repeated the
analysis for race/ethnicity and survival adjusting for age, cell type,
SES, urbanization, comorbid conditions, and treatment by stage
(data not presented in Table 3). Within each stage, Hispanic women
remained less likely to die of cervical cancer relative to non-His-
panic white women (localized stage: aHR, 0.30; later stage: aHR,
0.51; unknown stage: aHR, 0.50).
We also used multilevel logistic regression modeling for
these survival data and again noted similar effect estimates (rela-
tive risk vs hazard ratios) to those reported in Table 3 and much
wider CIs.
DISCUSSION
Compared with non-Hispanic white women, Hispanic
ethnicity was strongly associated with lower mortality rates in this
cohort of elderly (965 years) women whose conditions were diag-
nosed with cervical cancer in Texas. This association held when
simultaneously adjusting for age, stage, cell type, neighborhood
SES, urbanization, presence of a comorbid condition, and treatment
received. As anticipated, older women, those whose conditions
were diagnosed at a late or unknown stage, and those with a non-
squamous cervical cancer were more likely to die. Adjusting for
all factors, women receiving surgical treatment were less likely to
die of cervical cancer. Although we adjusted for stage, it is likely
that residual confounding may explain this finding because those
requiring surgery alone have localized disease. Neighborhood
SES and urbanization were not associated with survival.
We confirmed our finding of a lower mortality rate for
Hispanic women after adjusting for SES and urban residence, both
obtained from Census data, using multilevel logistic regression with
mortality as the outcome ignoring time to this event for the 3-year
TABLE 2. Multivariate predictors of treatment received for
women aged 65 years and older whose conditions were
diagnosed with cervical cancer and reported to the TCR from
1999 to 2001 using Medicare-linked treatment data
n
% Received
treatment*
Odds ratio
(95% CI)†
Age (continuous) 538 69.1 0.97 (0.94Y0.99)‡
Race/ethnicity
Non-Hispanic white 304 67.1 1.0 REF
Non-Hispanic black 99 66.7 0.87 (0.51Y1.49)
Hispanic 135 74.8 1.24 (0.73Y2.10)
Stage at diagnosis
Early 179 77.1 1.0 REF
Late 219 77.2 0.96 (0.59Y1.56)
Unknown 140 46.4 0.24 (0.14Y0.40)‡
Cell type
Nonsquamous 114 76.3 1.23 (0.74Y2.10)
Squamous cell 424 67.2 1.0 REF
SES§
High SES 136 61.8 1.0 REF
Mid SES 166 71.7 1.49 (0.88Y2.52)
Low SES 236 71.6 1.57 (0.93Y2.65)
Trend P = 0.11
Urbanization
Urban 418 67.5 1.0 REF
Large town 62 79.0 1.72 (0.86Y3.45)
Small town/rural 58 70.7 1.32 (0.68Y2.58)
Trend P = 0.21
Comorbid conditions
One or more 199 75.9 2.14 (1.39Y3.32)
None 339 65.2 1.00 REF
*Treatment includes 6 months before diagnosis and 1 year after
diagnosis.
†Adjusted for age (continuous), race, stage (ordinal), cell type, SES,
urbanization, and comorbid conditions (ordinal).
‡P G 0.01 for age and p G 0.001 for unknown stages at diagnosis.
§Socioeconomic status is a composite variable categorized into tertiles
based on the distribution of Texas residents.
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TABLE 3. Multivariate predictors of survival for women aged 65 years and older whose conditions were diagnosed with
cervical cancer and reported to the TCR from 1999 to 2001 using Medicare-linked treatment data
Demographic factors n*
All-cause survival Cervical cancerYspecific survival
Mortality rate† Hazard ratio‡ (95% CI) Mortality rate† Hazard ratio‡ (95%CI)
Age (continuous) 491 6.92 1.05 (1.03Y1.06)§ 3.56 1.04 (1.02Y1.07)§
Race/ethnicity
Non-Hispanic white 270 7.50 1.0 REF 3.97 1.0 REF
Non-Hispanic black 91 9.28 1.15 (0.85Y1.56) 5.08 1.28 (0.84Y1.93)
Hispanic 130 4.57 0.57 (0.41Y0.80)§ 1.99 0.48 (0.29Y0.79)§
Stage of diagnosis
Early stage 179 3.59 1.0 REF 1.49 1.0 REF
Late stage 219 10.86 2.72 (1.98Y3.73)§ 6.07 2.88 (1.83Y4.55)§
Unknown stage 93 7.63 2.00 (1.38Y2.91)§ 3.88 2.36 (1.38Y4.04)§
Cell type
Nonsquamous 177 8.30 1.30 (0.98Y1.73) 3.66 1.13 (0.74Y1.72)
Squamous 314 6.56 1.0 REF 3.53 1.00 REF
SES
High SES 116 6.68 1.0 REF 3.23 1.0 REF
Mid SES 154 6.50 0.96 (0.68Y1.35) 3.61 0.98 (0.61Y1.56)
Low SES 221 7.33 1.17 (0.84Y1.63) 3.70 1.12 (0.70Y1.80)
Trend P = 0.26 P = 0.58
Urbanization
Urban 381 6.54 1.0 REF 3.16 1.0 REF
Large town 55 8.48 1.36 (0.92Y2.0) 5.66 1.88 (1.15Y3.08)§
Small town/rural 55 8.33 1.32 (0.90Y1.93) 4.65 1.46 (0.86Y2.45)
Trend P = 0.08 P = 0.04
Comorbid conditions
One or more 177 8.35 1.40 (1.08Y2.81)§ 3.49 0.96 (0.75Y1.22)
None 314 6.20 1.0 REF 3.59 1.0 REF
No. conditions 1.25 (1.07Y1.47)§ 1.07 (0.83Y1.37)
Anemia at diagnosis¶
No 441 6.34 1.0 REF 3.20 1.0 REF
Yes 50 16.05 1.59 (1.11Y2.28)§ 9.29 1.53 (0.94Y2.50)
Treatment||
No treatment 128 8.81 1.0 REF 3.37 1.0 REF
Any treatment 363 6.35 0.68 (0.52Y0.89)§ 3.62 1.05 (0.70Y-1.59)
Days to first treatment P G 0.01 P G 0.01
All treatments||
No treatment 129 8.81 1.0 REF§ 3.37 1.0 REF§
Surgery/cone 49 3.00 0.43 (0.25Y0.76)§ 0.60 0.24 (0.07Y0.81)§
Radiation/chemotherapy 76 12.41 1.10 (0.74Y1.60) 7.31 1.63 (0.95Y2.79)
Radiation and chemotherapy 84 7.74 1.34 (0.78Y2.32) 5.32 2.14 (1.05Y5.37)§
Radiation, chemotherapy, and surgery 64 5.86 1.02 (0.6Y-1.70) 3.79 1.57 (0.79Y3.13)
Radiation/chemotherapy and surgery 90 4.51 0.52 (0.33Y0.81)§ 2.14 0.65 (0.33Y1.22)
No. chemotherapy 0.98 (0.95Y1.02) 0.98 (0.94Y1.02)
No. radiation 0.98 (0.96Y1.00) 0.99 (0.96Y1.02)
*Excludes those with survival = 0 days (n = 47).
†Mortality rate calculated per 10,000 woman-days.
‡Adjusted for age (continuous), race, stage (ordinal), cell type, SES, urbanization, comorbid conditions (ordinal), and treatment (type, combination, and
number of cycles).
§p G 0.001.
¶Anemia corresponds to the first case of documented anemia in Medicare records; anemia at diagnosis is within 30 days of cervical cancer diagnosis.
||Treatment includes 6 months before diagnosis and 1 year after diagnosis.
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period. As anticipated, the CIs were wider, yet the relative risk
estimates for all-cause and cervical cancerYspecific mortality for
Hispanic women relative to white women were 0.33 (0.14Y0.77) and
0.40 (0.23Y0.69), respectively. We present the hazard models be-
cause we lost follow-up data when we replaced logistic with Cox
modeling.
Our finding that Hispanic women were less likely to die
of cervical cancer contrasts with those of 2 published studies re-
porting that ethnicity was not an independent predictor of sur-
vival,8,17 yet is consistent with another large study conducted in
Texas independent of age.19 What might explain this finding? In this
Medicare-eligible population, Hispanic women were younger than
non-Hispanic white women; however, Hispanic women did not
differ from non-Hispanic whites in other factors predicting better
survival such as early stage diagnosis, no comorbid conditions,
squamous cell cancer, or treatment.
A social security number was required to merge the Medicare
and TCR databases. Therefore, the population included in this
analysis is not only older but also includes only US-born citizens or
those with documentation. However, in analyses independent of
documentation, a survival advantage for Hispanic women was still
observed.19
Our finding of reduced risk of death among Hispanic wo-
men with cervical cancer is similar to that reported for prostate
cancer survival46 in which prostate cancer cases identified through
SEER were linked with Medicare data. Survival rates by ethnicity
were adjusted for treatment, stage, age, and number of comorbid
conditions. Greater social support, particularly from extended fam-
ilies, may explain this finding. Genetic differences may also play a
role in explaining racial or ethnic differences in survival.46
A growing literature has addressed a BHispanic paradox[ in
mortality that is most pronounced among Mexican Americans.47
Some evidence supports this paradox being explained by selective
return migration toward the end of life, thus excluding those
migrating from the numerator when estimating mortality rates.
Improved survival for Hispanics may also be attributed to data
quality and completeness issues.48,49 Medicare-NUDIMENT data,
which avoid many problems inherent in vital statistics data, estimate
mortality by race/ethnicity; however, analyses using this superior
data source continue to reveal an attenuated but still significant
advantage for Hispanics.47 Others conclude that whereas selective
return migration and other data quality issues may explain some
component of the Hispanic mortality paradox, other cultural factors
including the Bsupportive aspects of Hispanic culture[ should be
empirically explored as explanatory factors in this phenomenon.50
Although we do not have data to evaluate the following
possibility, racial/ethnic differences in smoking may explain the
apparent Hispanic paradox observed in these data. Smoking, parti-
cularly in combination with high-risk human papillomavirus types,
is etiologically linked to preinvasive and invasive cancer.51Y54 An
emerging literature suggests that smoking may be linked to poor
cervical cancer survival in 3 studies55Y57 of 5 reports.55Y59 Preva-
lence of smoking differs dramatically by race/ethnicity in Texas.
On the basis of 2006 Behavioral Risk Factor Surveillance System
data for women 18 years and older, 38% of non-Hispanic white
women smoke compared with 31% non-Hispanic black and 18%
Hispanic women (Anna Vincent, Texas Department of State Health
Services, personal communication). If smoking is associated with a
2-fold increase in mortality and we apply the proportion of Texas
women who smoke to our data using external adjustment methods,60
Hispanic ethnicity is no longer significantly associated with a better
survival relative to non-Hispanic white women (P = 0.35). Although
we cannot empirically assess the aHR from our data, this observation
suggests that ethnic differences in smoking prevalence may explain
the observed Hispanic paradox in cervical cancer survival.
Our finding that non-Hispanic black race was not associated
with mortality relative to whites among this Medicare population
is consistent with those reported by Farley et al14 who used a large
military population with significant racial diversity yet similar ac-
cess to care. Farley et al found that race was not associated with
survival and posited that equal access to medical care may remove
the racial disparities in cancer incidence and survival. These findings
contrast with a recent large SEER-based study reported by Singh
et al20 who found a persistent association with lower SES and
poorer survival for women of all ages. Further, we found a survival
advantage for Hispanic women independent of SES. We hypo-
thesize that the differences in study findings may be a result of our
restriction to a sample with similar access to care (Medicare-
eligible women) and the ability to control for comorbid conditions
and treatment received. Because 92% of cervical cancer cases
had a Medicare claim and minority women were more likely to
have a claim than white women, there is some evidence that women
in this cohort had similar access to care.
Our finding that SES was not associated with survival after
adjusting for age, race, and stage at diagnosis is consistent with
5 other studies,4,10,18,61,62 although contrasting 4 others.12,13,19,21
Further, lower SES was not associated with age, stage, or cell type;
however, lower SES was associated with receiving any treatment
within 365 days of diagnosis (P G 0.05). These patterns suggest that
similar access to health care through Medicare eligibility may
explain why SES had no observed effect on survival.
In contrast with a similar Medicare-SEERYlinked analysis
of survival,18 we did not exclude cervical cancer cases whose care
was covered by primary private insurance. It is unlikely that we
have differentially included those with private care from other in-
surance sources. Because we only have Medicare claims data and
not other private insurance claims data, it is possible that we have
underestimated treatment received; however, based on Medicare
claims data, most women received treatment within 2 months. This
finding suggests that at least the first course of treatment in in-
cluded in the Medicare claims data.
Nonsquamous cervical cancers are not easily detected by
Papanicolaou tests63,64 and subsequently are at greater risk for late
stage diagnosis and poorer survival. We report here that women with
nonsquamous carcinomas had decreased all-cause mortality but not
cervical cancerYspecific survival when adjusting for stage at diag-
nosis and treatment received; thus, neither stage nor treatment re-
ceived explain this finding. Genetic differences in response to
treatment by cell type may play a role that we cannot evaluate in this
analysis.
Our finding that almost one quarter to one third of women
aged 65 years and older received no treatment based on Medicare
claims data is alarming. To explore potential issues with treatment
data quality based on Medicare claims data, we compared treatment
data from the TCR data. Rates of not receiving treatment based
on TCR data (n = 6320; 1998Y2003) for women aged 65 years
and older were 29% (n = 1320) and 17% for women younger than
65 years. Among women aged 65 years and older in the TCR data,
no significant differences in treatment rates by race/ethnicity were
observed. Cancer registry data regarding treatment can also be
incomplete, yet this comparison suggests that Medicare claims
data indicating that approximately 30% of women aged 65 years
and older with cervical cancer in Texas do not receive treat-
ment is accurate. Our finding that ethnic differences in receipt of
treatment based on claims data does suggest a problemwith access to
care in this Medicare-eligible population.
Several study limitations must be noted. Our sample size was
relatively small, and it limits the power for analyses by stage.
Because we are using existing data from Medicare and TCR, we
are restricted to the data available. Having additional data to more
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fully characterize stage, tumor size, human papillomavirus type,
smoking history, and other important predictors of survival was not
available. Although we have included potential confounders in
survival analyses models, residual confounding may still bias our
estimates.
Because data to characterize individual SES were not avai-
able, we used socioeconomic measures at the census tract level.
Thus, a potential for misclassification exists for variables included
in the TCR and Medicare files; however, these are not likely to be
differential with respect to the outcome because data were collected
before the outcome (time to mortality event). Further, the census
tract is the smallest unit of analysis available for our SES composite
variable.
This study adds to the existing literature3,8,18,20,27,65,66 on
using cancer registry data linked with Medicare claims history in
evaluating risk factors for survival among all elderly women whose
conditions were diagnosed with cervical cancer. In contrast to
hospital-based studies, registry-based studies are population-based
and include all incident cervical cancer cases in the community.
This study also adds to the existing literature as one of the few to
address cervical cancer survival among older women in a multi-
ethnic population. Finally, all women in the study have similar
access to medical care based on age-eligibility to Medicare.
However, our finding that ethnic differences in receipt of treatment
and survival suggests that having Medicare coverage does not mean
that older women with cervical cancer have similar access to care.
Challenges remain in providing women with cervical cancer
comprehensive health care coverage. Ethnic differences in social
support, knowledge of treatment options, patient-provider commu-
nication skills, and other logistic barriers to receipt of care may also
influence receipt of timely and appropriate treatment of cervical
cancer.
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